Schumacher TN - Search Results

1

Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy.

Kelderman S, Schumacher TN, Kvistborg P. Kelderman S, et al. Among authors: schumacher tn. Cancer Cell. 2015 Jul 13;28(1):11-3. doi: 10.1016/j.ccell.2015.06.012. Cancer Cell. 2015. PMID: 26175412

2

Assembly and intracellular transport of major histocompatibility complex molecules.

Neefjes JJ, Schumacher TN, Ploegh HL. Neefjes JJ, et al. Among authors: schumacher tn. Curr Opin Cell Biol. 1991 Aug;3(4):601-9. doi: 10.1016/0955-0674(91)90029-x. Curr Opin Cell Biol. 1991. PMID: 1837724 Review.

3

Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro.

Schumacher TN, Heemels MT, Neefjes JJ, Kast WM, Melief CJ, Ploegh HL. Schumacher TN, et al. Cell. 1990 Aug 10;62(3):563-7. doi: 10.1016/0092-8674(90)90020-f. Cell. 1990. PMID: 2199065

4

T-cell-receptor gene therapy.

Schumacher TN. Schumacher TN. Nat Rev Immunol. 2002 Jul;2(7):512-9. doi: 10.1038/nri841. Nat Rev Immunol. 2002. PMID: 12094225 Review.

5

Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice.

Verra NC, Jorritsma A, Weijer K, Ruizendaal JJ, Voordouw A, Weder P, Hooijberg E, Schumacher TN, Haanen JB, Spits H, Luiten RM. Verra NC, et al. Among authors: schumacher tn. Cancer Res. 2004 Mar 15;64(6):2153-61. doi: 10.1158/0008-5472.can-03-1339. Cancer Res. 2004. PMID: 15026357

6

On the role of melanoma-specific CD8+ T-cell immunity in disease progression of advanced-stage melanoma patients.

van Oijen M, Bins A, Elias S, Sein J, Weder P, de Gast G, Mallo H, Gallee M, Van Tinteren H, Schumacher T, Haanen J. van Oijen M, et al. Clin Cancer Res. 2004 Jul 15;10(14):4754-60. doi: 10.1158/1078-0432.CCR-04-0260. Clin Cancer Res. 2004. PMID: 15269149

7

Prospects and limitations of T cell receptor gene therapy.

Coccoris M, de Witte MA, Schumacher TN. Coccoris M, et al. Among authors: schumacher tn. Curr Gene Ther. 2005 Dec;5(6):583-93. doi: 10.2174/156652305774964730. Curr Gene Ther. 2005. PMID: 16457648 Review.

8

Selecting highly affine and well-expressed TCRs for gene therapy of melanoma.

Jorritsma A, Gomez-Eerland R, Dokter M, van de Kasteele W, Zoet YM, Doxiadis II, Rufer N, Romero P, Morgan RA, Schumacher TN, Haanen JB. Jorritsma A, et al. Among authors: schumacher tn. Blood. 2007 Nov 15;110(10):3564-72. doi: 10.1182/blood-2007-02-075010. Epub 2007 Jul 27. Blood. 2007. PMID: 17660381

9

Skewing the T-cell repertoire by combined DNA vaccination, host conditioning, and adoptive transfer.

Jorritsma A, Bins AD, Schumacher TN, Haanen JB. Jorritsma A, et al. Among authors: schumacher tn. Cancer Res. 2008 Apr 1;68(7):2455-62. doi: 10.1158/0008-5472.CAN-07-5254. Cancer Res. 2008. PMID: 18381454

10

An inducible caspase 9 safety switch can halt cell therapy-induced autoimmune disease.

de Witte MA, Jorritsma A, Swart E, Straathof KC, de Punder K, Haanen JB, Rooney CM, Schumacher TN. de Witte MA, et al. Among authors: schumacher tn. J Immunol. 2008 May 1;180(9):6365-73. doi: 10.4049/jimmunol.180.9.6365. J Immunol. 2008. PMID: 18424760

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results